138 related articles for article (PubMed ID: 35101932)
21.
van Leeuwen PJ; Emmett L
Eur Urol; 2022 Nov; 82(5):510-511. PubMed ID: 35787936
[No Abstract] [Full Text] [Related]
22. A Feasibility Study Showing [
Behr SC; Aggarwal R; Seo Y; Aparici CM; Chang E; Gao KT; Tao DH; Small EJ; Evans MJ
Mol Imaging Biol; 2016 Dec; 18(6):946-951. PubMed ID: 27184068
[TBL] [Abstract][Full Text] [Related]
23. Atypical metastatic pattern of prostate cancer detected with 68Ga-PSMA PET/CT.
Fech V; Sachpekidis C; Alberts I; Rominger A; Afshar-Oromieh A
Nuklearmedizin; 2020 Apr; 59(2):85-86. PubMed ID: 32189320
[No Abstract] [Full Text] [Related]
24. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
[TBL] [Abstract][Full Text] [Related]
25. Novel imaging strategies for prostate cancer.
J Koo P; Petrylak D
Future Oncol; 2021 Sep; 17(27):3545-3548. PubMed ID: 34251277
[No Abstract] [Full Text] [Related]
26. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A
Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603
[TBL] [Abstract][Full Text] [Related]
27. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
Rai BP; Baum RP; Patel A; Hughes R; Alonzi R; Lane T; Adshead J; Vasdev N
Urology; 2016 Sep; 95():11-5. PubMed ID: 26790588
[TBL] [Abstract][Full Text] [Related]
28. Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Skovgaard D; Persson M; Kjaer A
PET Clin; 2017 Apr; 12(2):243-255. PubMed ID: 28267457
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Accuracy of
Hicks RM; Simko JP; Westphalen AC; Nguyen HG; Greene KL; Zhang L; Carroll PR; Hope TA
Radiology; 2018 Dec; 289(3):730-737. PubMed ID: 30226456
[TBL] [Abstract][Full Text] [Related]
30. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
31. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
32. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
33. The frequency of thyroid incidental findings and risk of malignancy detected by
Gossili F; Petersen LJ; Zacho HD
Hell J Nucl Med; 2020; 23(3):240-245. PubMed ID: 33306753
[TBL] [Abstract][Full Text] [Related]
34. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
35. Recent Breakthrough in
Satpati D
Bioconjug Chem; 2021 Mar; 32(3):430-447. PubMed ID: 33630583
[No Abstract] [Full Text] [Related]
36. Role of
Can C; Gündoğan C; Yildirim OA; Poyraz K; Güzel Y; Kömek H
Hell J Nucl Med; 2021; 24(1):25-35. PubMed ID: 33866336
[TBL] [Abstract][Full Text] [Related]
37.
Draulans C; Pos F; Smeenk RJ; Kerkmeijer L; Vogel WV; Nagarajah J; Janssen M; Mai C; Heijmink S; van der Leest M; Zámecnik P; Oyen R; Isebaert S; Maes F; Joniau S; Kunze-Busch M; De Roover R; Defraene G; van der Heide UA; Goffin K; Haustermans K
Pract Radiat Oncol; 2021; 11(3):202-211. PubMed ID: 33941347
[TBL] [Abstract][Full Text] [Related]
38. FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discov; 2013 Jul; 3(7):OF1. PubMed ID: 23847352
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
40. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
